Myocardial infarction leads to loss of cardiomyocytes, scar formation, ventricular remodeling
and eventually deterioration of heart function. Over the past decade, stem cell therapy has …

Myocardial infarction (MI) is a major cause of morbidity and mortality worldwide. Until
recently, it was thought that myocardium was not able to repair itself, but studies have now …

Acute myocardial infarction (AMI) is the leading cause of cardiovascular death and remains
the most common cause of heart failure. Reopening of the occluded artery, ie, reperfusion, is …

Myocardial infarction is the leading cause of heart failure in developed countries. The
therapeutic measures of today are usually not sufficient to prevent left ventricular …

Skeletal myoblasts (SMs) transplantations are the focus of intense investigation due to their
therapeutic potential for cardiac repair. Heart diseases are the main problem in humans …

Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally,
and traditional pharmaceutical and surgical interventions delay the progression of CVDs …

The prognosis of patients with myocardial infarction (MI) and resultant chronic heart failure
remains extremely poor despite continuous advancements in optimal medical therapy and …

The possible different therapeutic efficacy of human mesenchymal stem cells (hMSC)
derived from umbilical cord blood (CB), adipose tissue (AT) or bone marrow (BM) for the …

Cardiovascular disease is now the leading cause of adult death in the world. According to
new estimates from the World Health Organization, myocardial infarction (MI) is responsible …

In recent years, mesenchymal stem cells (MSCs) have been used to improve cardiac
function and attenuate adverse ventricular remodeling of the ischemic myocardium through …